Moderna's mRNA flu vaccine surpasses standard shots in effectiveness

May 6, 2026, 11:00 PM10

(Update: May 6, 2026, 11:00 PM)

Moderna

American biotechnology company

science

innovative

ground breaking breakthrough

Moderna's mRNA flu vaccine surpasses standard shots in effectiveness

In a Phase 3 clinical trial, Moderna's mRNA flu vaccine outperformed standard flu shots with 27% increased protection.
The trial involved over 40,000 adults across 301 sites in 11 countries, focusing on older populations at greater risk.
The data from this trial may bolster chances for FDA approval and highlights the advantages of mRNA technology in rapid vaccine development.

Moderna

American biotechnology company

Insights

News 1

Related reports

Opinions

Story

“

analysis analysis geopolitical shift shift strategic economic geopolitical global global economic geopolitical strategic economic impact strategic economic geopolitical market trends shift data market geopolitical analysis geopolitical market analysis economic strategic insight geopolitical strategic impact trends shift economic market impact trends data strategic insight impact insight impact market trends insight analysis trends strategic insight trends global data policy market analysis geopolitical impact insight policy strategic trends economic trends geopolitical strategic trends strategic analysis impact global impact global strategic policy market insight...